BeOne Medicines (BEIGF) Interest & Investment Income (2015 - 2026)

BeOne Medicines (BEIGF) has reported Interest & Investment Income for 6 consecutive years, with $27.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 142.78% year-over-year to $27.9 million in Q2 2026; TTM through Jun 2026 was $116.7 million, a 80.69% increase from a year earlier, with the FY2025 full-year figure at $70.5 million, up 1.24% from the prior year.
• Interest & Investment Income was $27.9 million for Q2 2026 at BeOne Medicines, up from $27.7 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $58.1 million in Q4 2025 and troughed at $3.0 million in Q3 2025.
• A 4-year average of $21.5 million and a median of $18.4 million in 2023 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income sank 71.54% in 2025 and jumped 142.78% in 2026, its largest moves.
• Over 4 years, Interest & Investment Income stood at $20.6 million in 2023, then jumped by 43.49% to $29.6 million in 2024, then jumped by 96.3% to $58.1 million in 2025, then sank by 52.0% to $27.9 million in 2026.
• The last three Interest & Investment Income figures came in at $27.9 million (Q2 2026), $27.7 million (Q1 2026), and $58.1 million (Q4 2025), per Business Quant data.